REGULATED PRESS RELEASE published on 01/12/2024 at 17:45, 8 months 6 days ago NFL BIOSCIENCES CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME NFL BIOSCIENCES confirme son éligibilité au dispositif PEA PME pour l'année 2024, permettant l'intégration de ses actions dans les portefeuilles PEA PME. Prochaine publication financière : Résultats annuels 2023, le 29 mars 2024, après Bourse Euronext Growth Paris NFL Biosciences Médicaments Botaniques PEA PME Biopharmaceutique
REGULATED PRESS RELEASE published on 01/09/2024 at 17:45, 8 months 9 days ago NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024 NFL Biosciences, a biopharmaceutical company, has announced its financial communication calendar for 2024, including dates for annual results, Annual General Meeting, and half-year results. The company is known for developing botanical drug candidates for the treatment of addictions, such as NFL-101 for nicotine cessation and NFL-301 for reducing alcohol consumption. For more information, visit www.nflbiosciences.com. NFL Biosciences Biopharmaceutical Company Financial Calendar 2024 Botanical Drug Candidates Addiction Treatment
REGULATED PRESS RELEASE published on 01/09/2024 at 17:45, 8 months 9 days ago NFL BIOSCIENCES : AGENDA DE COMMUNICATION FINANCIÈRE 2024 La société biopharmaceutique NFL BIOSCIENCES annonce son calendrier de communication financière pour l'année 2024, incluant les résultats annuels 2023 et d'autres événements importants NFL Biosciences Médicaments Botaniques Communication Financière Résultats Annuels Biopharmaceutique
REGULATED PRESS RELEASE published on 01/08/2024 at 17:45, 8 months 10 days ago NFL BIOSCIENCES : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ 2ème SEMESTRE 2023
ARTICLE published on 12/19/2023 at 08:40, 8 months 30 days ago NFL Biosciences engage le processus d'approbation de la FDA pour son traitement contre l'alcoolisme NFL Biosciences vise à renforcer sa présence sur le marché pharmaceutique en proposant une nouvelle solution thérapeutique contre la dépendance à l'alcool NFL Biosciences FDA Pre-IND Consommation Excessive D'alcool Traitement Des Dépendances
REGULATED PRESS RELEASE published on 12/19/2023 at 08:00, 8 months 30 days ago NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNIS POUR NFL- 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL
REGULATED PRESS RELEASE published on 12/19/2023 at 08:00, 8 months 30 days ago NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FOR NFL-301, INDICATED FOR REDUCING ALCOHOL CONSUMPTION
REGULATED PRESS RELEASE published on 10/05/2023 at 19:00, 11 months 13 days ago NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
REGULATED PRESS RELEASE published on 10/05/2023 at 19:00, 11 months 13 days ago NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/18/2024 at 23:10, 3 hours 6 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 3 hours 16 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 5 hours 1 minute ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 5 hours 16 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 9 hours 46 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 7 hours 5 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 7 hours 31 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 7 hours 45 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 8 hours 3 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 8 hours 55 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 7 hours 31 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 7 hours 31 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 8 hours 36 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.